Xie, Mingchao
Vuko, Miljenka
Rodriguez-Canales, Jaime
Zimmermann, Johannes
Schick, Markus
O’Brien, Cathy
Paz-Ares, Luis
Goldman, Jonathan W.
Garassino, Marina Chiara
Gay, Carl M.
Heymach, John V.
Jiang, Haiyi
Barrett, J. Carl
Stewart, Ross A.
Lai, Zhongwu
Byers, Lauren A.
Rudin, Charles M.
Shrestha, Yashaswi
Article History
Received: 15 December 2023
Accepted: 3 May 2024
First Online: 30 May 2024
Declarations
:
: The study was conducted in accordance with the International Conference on Harmonisation good clinical practice guidelines, the Declaration of Helsinki, and applicable local regulations. All patients enrolled in CASPIAN provided written informed consent prior to study participation. The study protocol and all modifications was approved by the independent ethics committees or institutional review boards, and by the relevant regulatory authorities, for all 209 study sites.
: Not applicable.
: M.X., M.V., J.R.-C., J.Z., M.S., H.J., J.C.B., R.A.S., Z.L., and Y.S. are/were employees of AstraZeneca and may own stock or stock options. C.O’B. is a contractor for AstraZeneca. L.P.-A. has served on advisory councils or committees for Altum Sequencing and Stab Therapeutics, has received honoraria from AstraZeneca, Janssen, Merck, and Mirati, has received consulting fees from Eli Lilly, MSD, Roche, Pharmamar, Merck KgaA (Darmstadt, Germany), AstraZeneca, Novartis, Servier, Amgen, Pfizer, Bayer, Bristol-Myers Squibb, Mirati, GlaxoSmithKline, Janssen, Takeda, Regeneron, and Sanofi, and has received grants or funds from MSD, AstraZeneca, Bristol-Myers Squibb, Pfizer, and Pharmamar. J.W.G. reports research grants from AbbVie, AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck, consulting fees from AbbVie, AstraZeneca, Bristol-Myers Squibb, and Genentech, and support for travel from AstraZeneca. M.C.G. discloses competing financial interests with MSD Oncology, AstraZeneca/MedImmune, GlaxoSmithKline, Takeda, Roche, Bristol-Myers Squibb, Daiichi-Sankyo/AstraZeneca, Regeneron, Pfizer, Blueprint Medicines, Novartis, Sanofi-Aventis, and Medscape; holds advisory/management and consulting positions with Bristol-Myers Squibb, MSD, AstraZeneca, Novartis, Takeda, Roche, Sanofi-Aventis, Celgene, Daiichi-Sankyo, Pfizer, Seattle Genetics, Eli Lilly, GlaxoSmithKline, Bayer Healthcare Pharmaceuticals, Blueprint Medicines, Janssen, Regeneron, Bayer, AbbVie, Mirati, Merck, Boheringer Ingelheim, Blueprint Medicines, and Abion; is a member of a speakers bureau for AstraZeneca, MSD Oncology, Merck, Mirati, and Daiichi-Sankyo/AstraZeneca; and has received institutional research funding from Bristol-Myers Squibb, MSD, Roche/Genentech, AstraZeneca/MedImmune, AstraZeneca, Pfizer, GlaxoSmithKline, Novartis, Merck, Incyte, Takeda, Spectrum Pharmaceuticals, Blueprint Medicines, Eli Lilly, Ipsen, Janssen, Exelixis, MedImmune, Sanofi, and Amgen. C.M.G. discloses advisory/management and consulting positions with AstraZeneca, Bristol-Myers Squibb, Catalyst, Daiichi-Sankyo, G1 Therapeutics, Jazz Pharmaceuticals, Monte Rosa, and STCube; and holds Patent No. 11, 732, 306 (Molecular subtyping of small cell lung cancer to predict therapeutic responses). J.V.H. discloses scientific advisory boards for AstraZeneca and Genentech; patent applications pending on SCLC classification; research funding from AstraZeneca; and that MD Anderson has licensing agreements with Nucleix and BostonGene for the development of biomarkers for SCLC subgroups. L.A.B. discloses advisory/management and consulting positions with MSD, Arrowhead Pharmaceuticals, Chugai Pharmaceutical Co., AstraZeneca, Genentech, BeiGene, AbbVie, Jazz Pharmaceuticals, Puma Biotechnology, Amgen, and Daiichi-Sankyo; and holds Patent No. 11, 732, 306 (Molecular subtyping of small cell lung cancer to predict therapeutic responses). C.M.R. has consulted regarding oncology drug development with AbbVie, Amgen, AstraZeneca, D2G, Daiichi-Sankyo, Epizyme, Genentech/Roche, Ipsen, Jazz, Kowa, Eli Lilly, Merck, and Syros; and serves on the scientific advisory boards of Auron, Bridge Medicines, DISCO, Earli, and Harpoon Therapeutics.
: We support inclusive, diverse, and equitable conduct of research. We worked to ensure gender balance in the recruitment of human subjects. We worked to ensure ethnic or other types of diversity in the recruitment of human subjects. We worked to ensure that the study questionnaires were prepared in an inclusive way. One or more of the authors of this paper self-identifies as a member of the LGBTQIA + community. One or more of the authors of this paper self-identifies as a gender minority in their field of research. While citing references scientifically relevant for this work, we also actively worked to promote gender balance in our reference list.